Mauro Zaffaroni

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN)

Luca Durelli, E. Verdun, Pierangelo Barbero et al. · The Lancet · 2002 · 549 citations

Life Sciences, Immunology, Neurology +6

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei‐Ran Ho, Nolan Campbell et al. · The Lancet Neurology · 2018 · 337 citations · Full text

Life Sciences, Neurology, Pharmacotherapy +14

Multiple sclerosis in childhood: clinical features of 149 cases

Angelo Ghezzi, Valeria Deplano, J. Faroni et al. · Multiple Sclerosis Journal · 1997 · 307 citations

Medicine, Neurology, Pediatrics +15

Clinical characteristics, course and prognosis of relapsing Devic?s Neuromyelitis Optica

Angelo Ghezzi, Roberto Bergamaschi, Vittorio Martinelli et al. · Journal of Neurology · 2004 · 267 citations

Medicine, Neurology, Pathology +9

Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial

Diego Cadavid, Michelle Mellion, Raymond Hupperts et al. · The Lancet Neurology · 2019 · 185 citations

Life Sciences, Immunology, Neurology +11